Controversial Trial Discovers No Benefit For Expensive The Medicines Company (MDCO) Drug
7/8/2014 6:30:00 AM
Although there is broad consensus in the medical community that immediate stenting (primary PCI) is the best treatment for heart attack patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company MDCO -2.7%) has been particularly uncertain because it is far more expensive than its alternative, unfractionated heparin.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by